Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Synlogic, Inc. Reports $3.87 Million Net Loss for Q3 2026 Amid Caldera Merger Deal

Synlogic, Inc. reported a net loss of $3.87 million for the third quarter of 2026, a 68.3% increase in loss compared to the prior year. The company has discontinued its clinical operations and is currently moving forward with a definitive merger agreement with Caldera Therapeutics, Inc. to maximize remaining asset value.

Types of galaxies, galaxy types, different galaxies, galaxy. Stock photo illustrating Synlogic's financial results story.
SYNLOGIC, INC. · Photo: WikiImages / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 0.000.00
Net Income -3.87-2.30
Diluted EPS -0.31-0.19
Net Income YoY
-68.3%

Key highlights

  • Net loss widened to $3.87 million in Q3 2026 from $2.30 million in the prior year period
  • Revenue remained at $0.00 for the quarter as the company discontinued its clinical programs
  • Diluted earnings per share decreased to -$0.31 compared to -$0.19 in Q3 2025
  • Cash and cash equivalents totaled $11.6 million as of September 30, 2026
  • Restructuring and transaction-related charges were the primary drivers of the quarterly deficit

How the Period Went

Synlogic, Inc. reported a zero-revenue quarter for the period ended September 30, 2026, consistent with the same period in 2025. The company’s net loss widened to $3.87 million, compared to a $2.30 million loss in the prior year. This represents a 68.3% increase in the net loss during the transition period. Diluted earnings per share also moved further into negative territory, reaching -$0.31 compared to -$0.19 in the third quarter of 2025. These figures highlight a period of increased spending despite the lack of commercial operations, driven by the company's significant structural shift.

Margins and Profitability

The widening net loss was largely a result of non-recurring expenses associated with the company’s strategic reorganization. Specifically, restructuring charges and transaction-related costs pushed the net loss to $3.87 million. As Synlogic has moved away from active research, the absence of revenue means that all operational and administrative outlays contribute directly to the bottom-line deficit. The company’s focus has shifted from clinical development to managing the financial obligations of its wind-down and the legal complexities of its pending merger with Caldera Therapeutics, which has created a temporary spike in professional services expenses.

Business Overview

Synlogic, Inc. is a biotechnology firm that historically specialized in Synthetic Biotic medicines, which are genetically engineered microbes designed to treat metabolic disorders. Following a comprehensive strategic review, the company has moved to discontinue all clinical trials and reduce its workforce. Currently, Synlogic’s primary business activity involves the execution of a merger agreement with Caldera Therapeutics, Inc. This strategic pivot is intended to preserve remaining capital and explore alternative paths for the company's asset base and technological platform within a combined corporate entity.

Financial Context

Synlogic’s financial position is defined by its transition toward a strategic exit. The $3.87 million net loss in the third quarter of 2026 reflects a widening deficit compared to the $2.30 million loss recorded in the same period last year. With no revenue generated during either period, the company’s burn rate is currently focused on fulfilling obligations related to its discontinued operations and upcoming merger. The ending cash and cash equivalents balance of $11.6 million provides a finite runway to finalize the transaction with Caldera Therapeutics, signaling the conclusion of Synlogic's independent research phase.

Industry Landscape

The biotechnology sector is currently characterized by heightened consolidation as development-stage firms navigate challenging funding environments and clinical hurdles. Synlogic’s decision to halt its programs and seek a merger aligns with broader industry trends where small-cap biotech companies prioritize cash preservation over high-risk research. By terminating its clinical pipeline, Synlogic has joined a cohort of biotech entities prioritizing strategic combinations. This environment favors companies with remaining liquidity, like Synlogic’s $11.6 million, which can be leveraged to facilitate corporate combinations in a tightening financial landscape for pre-revenue entities.

Source verified

SEC filing by Synlogic, Inc. announcing its third quarter 2026 financial results.

Read the filing ↗

Track SYNLOGIC, INC. live

Get the next SYNLOGIC, INC. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.